Shortfalls in clinical trial recruitment and retention constitute a major obstacle to scientific advancement.1 One means of increasing patient participation rates is to reduce associated financial burdens. In several states, efforts are under way to achieve this goal for patients in cancer clinical trials through legislation explicitly allowing reimbursement of certain clinical trial–related expenses. Although laudable, these efforts fall far short. Financial barriers to participation exist beyond the confines of oncology, and singling out reimbursement fails to take advantage of other ethically permissible functions of offering payment, including compensating for research-related burden and incentivizing participation.
Largent EA, Lynch HF. Addressing Financial Barriers to Enrollment in Clinical Trials. JAMA Oncol. 2018;4(7):913–914. doi:10.1001/jamaoncol.2018.0492
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: